

Date: 07-02-2015

To,  
The Secretary,  
The Bombay Stock  
Exchange Limited  
Floor 25, P.J. Towers,  
Dalal Street,  
Mumbai. - 400 001

The Manager (Listing  
Department)  
The Ahmedabad Stock  
Exchange Ltd.,  
Kamadhenu Complex,  
Opp. Sahajanand College,  
Panjarapole,  
Ahmedabad

To,  
The Manager (Listing  
Department)  
The Madras Stock  
exchange,  
Chennai

**Sub : Outcome of the Board meeting.**

The meeting of the Board of Directors of the company was held at 04:30 pm today. The outcome of the meeting is under:

The Board has considered and approved the minutes of the previous board meeting.

The Board has considered and approved the Standalone and Consolidated Un-Audited Financials for the Quarter 31<sup>st</sup> December, 2014.

There being no other matter meeting of the board of directors concluded with the vote of thanks.

Thanking you

Yours truly,  
for **TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED.**



**ARVIND KUMAR BHANGADIA**  
Managing Director  
DIN:00015838

**TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED**  
 CONSOLIDATED UN-AUDITED QUARTERLY RESULTS FOR THE QUARTER ENDED DECEMBER, 2014

**TRIMURTHI**  
 GROUP

**PART-I**

(Rs. In Lakhs)

Particulars	3 Months ended 31-12-2014	Preceeding 3 months ended 30-09-2014	Corresponding 3 months ended 31-12-2013	Year to date figures for the current period ended 31-12-2014	Year to date figures for the current period ended 31-12-2013	Year ended 31-03-2014
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>1. Income From Operations</b>						
Net Sales / Income from Operations	128.65	131.64	109.61	411.17	345.12	484.75
Other Operating Income	29.05	29.00	27.20	83.47	77.66	91.13
<b>Total Operating Income(Net)</b>	<b>157.70</b>	<b>160.64</b>	<b>136.81</b>	<b>494.64</b>	<b>422.78</b>	<b>575.88</b>
<b>2. Expenditure</b>						
a. Consumption of Raw Material	Nil	Nil	Nil	Nil	Nil	
b. Purchase of Traded Goods	131.24	113.65	104.73	376.60	324.64	422.95
c. (Increase)/Decrease in stock in trade and work in Progress	(20.40)	0.27	(5.01)	(17.12)	(19.64)	1.07
d. Employees Cost	8.29	5.63	9.37	18.68	18.74	33.13
e. Depreciation	8.15	7.71	7.55	23.52	21.35	28.53
f. Other Expenditure	8.52	6.20	5.95	23.85	19.28	28.62
<b>Total</b>	<b>135.81</b>	<b>133.45</b>	<b>122.58</b>	<b>425.54</b>	<b>364.36</b>	<b>514.30</b>
<b>Profit/ (Loss) from Operations before Other Income, Finance Cost &amp; Exceptional Items (2-1)</b>	<b>21.89</b>	<b>27.19</b>	<b>14.23</b>	<b>69.11</b>	<b>58.42</b>	<b>61.58</b>
<b>4. Other Income</b>						
<b>Profit/ (Loss) from Ordinary Acitivites before Finance Cost &amp; Exceptional Items (3+4)</b>	<b>21.89</b>	<b>27.19</b>	<b>14.23</b>	<b>69.11</b>	<b>58.42</b>	<b>61.58</b>
<b>6. Finance Cost</b>	<b>0.11</b>	<b>0.15</b>	<b>0.15</b>	<b>0.26</b>	<b>0.51</b>	<b>0.64</b>
<b>7. Profit/ (Loss) from Ordinary activities after finance cost but before exceptional items (5+6)</b>	<b>21.78</b>	<b>27.04</b>	<b>14.08</b>	<b>68.85</b>	<b>57.91</b>	<b>60.94</b>
<b>8. Exceptional Items</b>	Nil	Nil	Nil	Nil	Nil	Nil
<b>9. Profit/ (Loss) from Ordinary activities before tax (7+8)</b>	<b>21.78</b>	<b>27.04</b>	<b>14.08</b>	<b>68.85</b>	<b>57.91</b>	<b>60.94</b>
<b>10. Tax Expense (Including Deferred Tax)</b>	7.27	8.38	4.54	21.67	19.90	19.36
<b>11. Net Profit/ (Loss) from Ordinary activities after Tax (9±10)</b>	<b>14.51</b>	<b>18.66</b>	<b>9.54</b>	<b>47.18</b>	<b>38.01</b>	<b>41.58</b>
<b>12. Extraoridnary Items(Net Of Tax Expenses)</b>	Nil	Nil	Nil	Nil	Nil	Nil
<b>13. Net Profit/ (Loss) for the period (11+12)</b>	<b>14.51</b>	<b>18.66</b>	<b>9.54</b>	<b>47.18</b>	<b>38.01</b>	<b>41.58</b>
<b>14. Share Of Profit/(loss) Of Associates</b>	-NA-	-NA-	-NA-	-NA-	-NA-	-NA-
<b>15. Minority Interest</b>	<b>1.28</b>	<b>0.63</b>	<b>-NA-</b>	<b>7.93</b>	<b>-NA-</b>	<b>-NA-</b>
<b>16. Net Profit/ (Loss) after taxes, Minority Interest and Share Of Profit/(Loss) of Associates (13+14+15)</b>	<b>13.23</b>	<b>18.03</b>	<b>9.54</b>	<b>39.25</b>	<b>38.01</b>	<b>41.58</b>
<b>17. Paid-up Equity Share Capital (Face Value of Rs.10/- each)</b>	810.00	810.00	810.00	810.00	810.00	810.00
<b>18. Reserves excluding revaluation reserves as per balance sheet of previous accounting year</b>	334.84	334.84	293.26	334.84	293.26	293.26
<b>19. Earnings Per Share (EPS)</b>						
<b>i. Basic &amp; Diluted before extraordinary items (not annualised)</b>	<b>0.16</b>	<b>0.22</b>	<b>0.12</b>	<b>0.48</b>	<b>0.47</b>	<b>0.51</b>
<b>ii. Basic &amp; Diluted after extraordinary items (not annualised)</b>	<b>0.16</b>	<b>0.22</b>	<b>0.12</b>	<b>0.48</b>	<b>0.47</b>	<b>0.51</b>

For Trimurthi Drugs & Pharmaceuticals Ltd.

Managing Director

**Trimurthi Drugs & Pharmaceuticals Ltd.**

4-4-231/1/2 ABC, Inder Bagh, Sultan Bazar,  
 Hyderabad - 500 095, A.P., India

T: 040 2475 7270

W: [www.trimurthigroup.com](http://www.trimurthigroup.com) CIN No: L67120101994PLC018930



**TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED**  
**CONSOLIDATED UN-AUDITED QUARTERLY RESULTS FOR THE QUARTER ENDED DECEMBER, 2014**

**PART-II**

**Select Information for Quarter III and Nine Months Ended 31/12/2014**

<b>Particulars</b>	<b>3 Months ended</b>	<b>Preceeding 3 months ended</b>	<b>Corresponding 3 months ended</b>	<b>Year to date figures for the current period</b>	<b>Year to date figures for the current period</b>	<b>Year ended 31-03-2014</b>
	<b>31-12-2014</b>	<b>30-09-2014</b>	<b>Unaudited</b>	<b>Unaudited</b>	<b>Unaudited</b>	<b>Audited</b>
<b>A. Particulars Of Share Holding</b>						
1. Public Share Holding						
- Number of Shares	3102200	3102200	3366200	3102200	3366200	3166200
- Percentage of shareholding	38.30%	38.30%	41.56%	38.30%	41.56%	39.09%
2. Promoters and promoter group shareholding						
a. Pledged / encumbered						
- No of Equity Shares	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (of the shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil	Nil
b. Non encumbered						
- No of Equity Shares	4997800	4997800	4733800	4997800	4733800	4933800
- Percentage of Shares (of the shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of Shares (of the total share capital of the company)	61.70%	61.70%	58.44%	61.70%	58.44%	60.91%
<b>Particulars</b>						
<b>B. Investor Complaints</b>						
Pending at the beginning of the quarter				-NIL-		
Received during the quarter				-NIL-		
Disposed during the quarter				-NIL-		
Remaining unsolved during the quarter				-NIL-		

**Segment Reporting**

<b>Particulars</b>	<b>Quarters ended</b>			<b>Nine Months Ended</b>		<b>Year ended</b>
	<b>31/12/2014</b>	<b>30/09/2014</b>	<b>31/12/2013</b>	<b>31/12/2014</b>	<b>31/12/2013</b>	<b>31/03/2014</b>
	<b>Unaudited</b>	<b>Unaudited</b>	<b>Unaudited</b>	<b>Unaudited</b>	<b>Unaudited</b>	<b>Audited</b>
1. <b>Segment Revenue</b>						
a. Pharma Business	128.65	131.64	113.01	411.17	353.12	486.39
b. Financial Services	29.05	29.00	23.79	83.47	69.65	89.48
c. Investments	0.00	0.00	0.01	0.00	0.01	0.01
d. Trading in Shares	0.00	0.00	0.00	0.00	0.00	0.00
<b>Total</b>	<b>157.70</b>	<b>160.64</b>	<b>136.81</b>	<b>494.64</b>	<b>422.78</b>	<b>575.88</b>
<b>Less: Inter Segment Revenue</b>	<b>-Nil-</b>	<b>-Nil-</b>	<b>-Nil-</b>	<b>-Nil-</b>	<b>-Nil-</b>	<b>-Nil-</b>
<b>Net Sales/ Income From Operations</b>	<b>157.70</b>	<b>160.64</b>	<b>136.81</b>	<b>494.64</b>	<b>422.78</b>	<b>575.88</b>
2. <b>Segment Profits ( Before tax &amp; Interest From Each Segment)</b>						
a. Pharma Business	7.65	13.14	(7.20)	27.52	(6.19)	(19.51)
b. Financial Services	14.13	13.90	21.27	41.33	64.09	80.44
c. Investments	0.00	0.00	0.01	0.00	0.01	0.01
d. Trading in Shares	0.00	0.00	0.00	0.00	0.00	0.00
<b>Total</b>	<b>21.78</b>	<b>27.04</b>	<b>14.08</b>	<b>68.85</b>	<b>57.91</b>	<b>60.94</b>
<b>Less:</b>						
i. Interest	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
ii. Other Un-allocable expenses net off	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
iii. Un-allocable Income	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
<b>Total Profit Before Tax</b>	<b>21.78</b>	<b>27.04</b>	<b>14.08</b>	<b>68.85</b>	<b>57.91</b>	<b>60.94</b>
3. <b>Capital Employed</b>						
a. Pharma Business	127.52	75.39	360.31	127.52	360.31	392.88
b. Financial Services	1026.58	1032.21	727.33	1026.58	727.33	681.82
c. Investments	5.00	31.50	12.49	5.00	12.49	31.50
d. Trading in Shares	0.00	0.00	0.00	0.00	0.00	0.00
<b>Total</b>	<b>1159.09</b>	<b>1139.10</b>	<b>1100.13</b>	<b>1159.09</b>	<b>1100.13</b>	<b>1106.20</b>

**Notes:**

1. The above results have been taken on record by the board of directors of the company at their meeting held on 07-02-2015
2. The financial results for the quarter ended 31-12-2014 have been reviewed by the statutory auditors in pursuance of listing agreement
3. In segment reporting common assets that are used interchangeable not allocated to the individual segment above.

Place: Hyderabad,  
Date : 07-02-2015.

Managing Director

**Trimurthi Drugs & Pharmaceuticals Ltd.**

4-4-231/1/2 ABC, Inder Bagh, Sultan Bazar,  
Hyderabad - 500 095, A.P., India

T: 040 2475 7370

W: [www.trimurthigroup.com](http://www.trimurthigroup.com)

CIN No: L67120TG1994PLC018956

**TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED**  
STANDALONE UN-AUDITED QUARTERLY RESULTS FOR THE QUARTER ENDED DECEMBER, 2014

**PART-I**

Particulars	(Rs. In Lakhs)					
	3 Months ended 31-12-2014	Preceeding 3 months ended 30-09-2014	Corresponding 3 months ended 31-12-2013	Year to date figures for the current period ended 31-12-2014	Year to date figures for the current period ended 31-12-2013	Year ended 31-03-2014
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>1. Income From Operations</b>						
Net Sales / Income from Operations	0.00	(0.00)	109.61	31.40	345.12	486.39
Other Operating Income	30.83	26.13	27.20	83.47	77.66	89.48
<b>Total Operating Income(Net)</b>	<b>30.83</b>	<b>26.13</b>	<b>136.81</b>	<b>114.87</b>	<b>422.78</b>	<b>575.87</b>
<b>2. Expenditure</b>						
a. Consumption of Raw Material	Nil	Nil	Nil	Nil	Nil	
b. Purchase of Traded Goods	0.00	0.00	104.73	0.08	324.64	422.95
c. (Increase)/Decrease in stock in trade and work in Progress	0.00	0.00	(5.01)	32.21	(19.64)	1.07
d. Employees Cost	1.42	0.97	9.37	3.85	18.74	33.13
e. Depreciation	7.21	7.67	7.55	22.54	21.35	28.53
f. Other Expenditure	5.25	3.46	5.95	15.08	19.28	28.62
<b>Total</b>	<b>13.87</b>	<b>12.10</b>	<b>122.58</b>	<b>73.76</b>	<b>364.36</b>	<b>514.30</b>
<b>Profit/ (Loss) from Operations before Other Income, Finance Cost &amp; Exceptional Items (2-1)</b>						
<b>4. Other Income</b>	<b>16.96</b>	<b>14.04</b>	<b>14.23</b>	<b>41.10</b>	<b>58.42</b>	<b>61.57</b>
<b>5. Profit/ (Loss) from Ordinary Activities before Finance Cost &amp; Exceptional Items (3±4)</b>	<b>16.96</b>	<b>14.04</b>	<b>14.23</b>	<b>41.10</b>	<b>58.42</b>	<b>61.57</b>
<b>6. Finance Cost</b>	<b>0.11</b>	<b>0.15</b>	<b>0.15</b>	<b>0.26</b>	<b>0.51</b>	<b>0.64</b>
<b>7. Profit/ (Loss) from Ordinary activities after finance cost but before exceptional items (5+6)</b>	<b>16.85</b>	<b>13.89</b>	<b>14.08</b>	<b>40.84</b>	<b>57.91</b>	<b>60.93</b>
<b>8. Exceptional Items</b>	<b>Nil</b>	<b>Nil</b>	<b>Nil</b>	<b>Nil</b>	<b>Nil</b>	<b>Nil</b>
<b>9. Profit/ (Loss) from Ordinary activities before tax (7±8)</b>	<b>16.85</b>	<b>13.89</b>	<b>14.08</b>	<b>40.84</b>	<b>57.91</b>	<b>60.93</b>
<b>10. Tax Expense (Including Deferred Tax)</b>	<b>5.21</b>	<b>4.29</b>	<b>4.54</b>	<b>13.00</b>	<b>19.90</b>	<b>19.36</b>
<b>11. Net Profit/ (Loss) from Ordinary activities after Tax (9±10)</b>	<b>11.64</b>	<b>9.59</b>	<b>9.54</b>	<b>27.85</b>	<b>38.01</b>	<b>41.57</b>
<b>12. Extraordinary Items(Net Of Tax Expenses)</b>	<b>Nil</b>	<b>Nil</b>	<b>Nil</b>	<b>Nil</b>	<b>Nil</b>	<b>Nil</b>
<b>13. Net Profit/ (Loss) for the period (11±12)</b>	<b>11.64</b>	<b>9.59</b>	<b>9.54</b>	<b>27.85</b>	<b>38.01</b>	<b>41.57</b>
<b>14. Share Of Profit/(loss) Of Associates</b>	<b>-NA-</b>	<b>-NA-</b>	<b>-NA-</b>	<b>-NA-</b>	<b>-NA-</b>	<b>-NA-</b>
<b>15. Minority Interest</b>	<b>-NA-</b>	<b>-NA-</b>	<b>-NA-</b>	<b>-NA-</b>	<b>-NA-</b>	<b>-NA-</b>
<b>Net Profit/ (Loss) after taxes, Minority Interest and Share Of Profit/(Loss) of</b>						
<b>16. Associates (13+14+15)</b>	<b>11.64</b>	<b>9.59</b>	<b>9.54</b>	<b>27.85</b>	<b>38.01</b>	<b>41.57</b>
Paid-up Equity Share Capital (Face Value of						
17. Rs.10/- each)	810.00	810.00	810.00	810.00	810.00	810.00
Reserves excluding revaluation reserves as per						
18. balance sheet of previous accounting year	334.84	334.84	293.26	334.84	293.26	293.26
<b>19. Earnings Per Share (EPS)</b>						
<b>i. Basic &amp; Diluted before extraordinary items (not annualised)</b>	<b>0.14</b>	<b>0.12</b>	<b>0.12</b>	<b>0.34</b>	<b>0.47</b>	<b>0.51</b>
<b>ii. Basic &amp; Diluted after extraordinary items (not annualised)</b>	<b>0.14</b>	<b>0.12</b>	<b>0.12</b>	<b>0.34</b>	<b>0.47</b>	<b>0.51</b>

For Trimurthi Drugs & Pharmaceuticals Ltd



Managing Director

**Trimurthi Drugs & Pharmaceuticals Ltd.**

4-4-231/1/2 ABC, Inder Bagh, Sultan Bazar,  
Hyderabad - 500 095, A.P., India

T: 040 2475 7370

W: [www.trimurthigroup.com](http://www.trimurthigroup.com)

CIN No: L67120TS1994PLC018956

**TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED**

STANDALONE UN-AUDITED QUARTERLY RESULTS FOR THE QUARTER ENDED DECEMBER, 2014

**PART-II**

**SELECT INFORMATION FOR QUARTER III AND NINE MONTHS ENDED 31-12-2014**

<b>Particulars</b>	<b>3 Months ended 31-12-2014</b>	<b>Preceeding 3 months ended 30-09-2014</b>	<b>Corresponding 3 months ended 31-12-2013</b>	<b>Year to date figures for the current period ended 31-12-2014</b>	<b>Year to date figures for the current period ended 31-12-2013</b>	<b>Year ended 31-03-2014</b>
	<b>Unaudited</b>	<b>Unaudited</b>	<b>Unaudited</b>	<b>Unaudited</b>	<b>Unaudited</b>	<b>Audited</b>
<b>A. Particulars Of Share Holding</b>						
1. Public Share Holding						
- Number of Shares	3102200	3102200	3366200	3102200	3366200	3166200
- Percentage of shareholding	38.30%	38.30%	41.56%	38.30%	41.56%	39.09%
2. Promoters and promoter group shareholding						
a. Pledged / encumbered						
- No of Equity Shares	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (of the shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil	Nil
b. Non encumbered						
- No of Equity Shares	4997800	4997800	4733800	4997800	4733800	4933800
- Percentage of Shares (of the shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of Shares (of the total share capital of the company)	61.70%	61.70%	58.44%	61.70%	58.44%	60.91%

<b>Particulars</b>	<b>3 Months Ended ( 31/12/2014)</b>
<b>B. Investor Complaints</b>	
Pending at the beginning of the quarter	-NIL-
Received during the quarter	-NIL-
Disposed during the quarter	-NIL-
Remaining unsolved during the quarter	-NIL-

**Segment Reporting**

<b>Particulars</b>	<b>Quarters ended</b>			<b>Nine Months Ended</b>		<b>Year ended</b>
	<b>31/12/2014</b>	<b>30/09/2014</b>	<b>31/12/2013</b>	<b>31/12/2014</b>	<b>31/12/2013</b>	<b>31/03/2014</b>
	<b>Unaudited</b>	<b>Unaudited</b>	<b>Unaudited</b>	<b>Unaudited</b>	<b>Unaudited</b>	<b>Audited</b>
<b>1. Segment Revenue</b>						
a. Pharma Business	0.00	0.00	113.01	31.40	353.12	486.39
b. Financial Services	30.83	26.13	23.79	83.47	69.65	89.48
c. Investments	0.00	0.00	0.01	0.00	0.01	0.00
d. Trading in Shares	0.00	0.00	0.00	0.00	0.00	0.00
<b>Total</b>	<b>30.83</b>	<b>26.13</b>	<b>136.81</b>	<b>114.87</b>	<b>422.78</b>	<b>575.87</b>
<b>Less: Inter Segment Revenue</b>	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
<b>Net Sales/ Income From Operations</b>	<b>30.83</b>	<b>26.13</b>	<b>136.81</b>	<b>114.87</b>	<b>422.78</b>	<b>575.87</b>
<b>2. Segment Profits ( Before tax &amp; Interest From Each Segment)</b>						
a. Pharma Business	0.00	0.00	(7.20)	(1.47)	(6.19)	(19.51)
b. Financial Services	16.85	13.89	21.27	42.31	64.09	80.44
c. Investments	0.00	0.00	0.01	0.00	0.01	0.00
d. Trading in Shares	0.00	0.00	0.00	0.00	0.00	0.00
<b>Total</b>	<b>16.85</b>	<b>13.89</b>	<b>14.08</b>	<b>40.84</b>	<b>57.91</b>	<b>60.93</b>
<b>Less:</b>						
i. Interest	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
ii. Other Un-allocable expenses net off	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
iii. Un-allocable Income	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
<b>Total Profit Before Tax</b>	<b>16.85</b>	<b>13.89</b>	<b>14.08</b>	<b>40.84</b>	<b>57.91</b>	<b>60.93</b>
<b>3. Capital Employed</b>						
a. Pharma Business	16.66	18.98	360.31	16.66	360.31	392.88
b. Financial Services	1099.53	1080.57	727.33	1099.53	727.33	681.82
c. Investments	31.50	31.50	12.49	31.50	12.49	31.50
d. Trading in Shares	0.00	0.00	0.00	0.00	0.00	0.00
<b>Total</b>	<b>1147.69</b>	<b>1131.05</b>	<b>1100.13</b>	<b>1147.69</b>	<b>1100.13</b>	<b>1106.20</b>

**Notes:**

1. The above results have been taken on record by the board of directors of the company at their meeting held on 07-02-2015.
2. The financial results for the quarter ended 31-12-2014 have been reviewed by the statutory auditors in pursuance of listing agreement.
3. In segment reporting common assets that are used interchangeable not allocated to the individual segment above.

Place: Hyderabad,  
Date: 07-02-2015

Trimurthi Drugs & Pharmaceuticals Ltd.  
Managing Director

Trimurthi Drugs & Pharmaceuticals Ltd.

4-4-231/1/2 ABC, Inder Bagh, Sultan Bazar,  
Hyderabad - 500 095, A.P., India

T: 040 2453300

CIN No: T67100TG1004PLC018056